Foxo4-DRI at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Foxo4-DRI is a D-amino acid retro-inverso peptide designed to interfere with the interaction between Foxo4 and p53 specifically in senescent cells. Senescent cells - sometimes called "zombie cells" - are cells that have irreversibly stopped dividing but resist apoptosis and secrete a pro-inflammatory cocktail called the SASP (senescence-associated secretory phenotype) that damages surrounding tissue.
In senescent cells, the Foxo4 transcription factor sequesters p53 in the nucleus, preventing p53 from triggering apoptosis. Foxo4-DRI mimics the Foxo4 binding domain and outcompetes endogenous Foxo4, freeing p53 to initiate apoptosis selectively in senescent cells while leaving normal cells unaffected. This makes it one of the most targeted senolytic mechanisms discovered to date.
In a landmark 2017 Nature Medicine study, Foxo4-DRI demonstrated dramatic physical rejuvenation in aged mice - restoring fur density, exercise tolerance, and renal function. It also showed efficacy in chemotherapy-induced senescence models. Human data remains absent and the peptide is highly experimental, but it represents the most mechanistically targeted approach to senescent cell clearance currently available.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.